| __timestamp | BioCryst Pharmaceuticals, Inc. | Johnson & Johnson |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 21954000000 |
| Thursday, January 1, 2015 | 13047000 | 21203000000 |
| Friday, January 1, 2016 | 11253000 | 19945000000 |
| Sunday, January 1, 2017 | 13933000 | 21420000000 |
| Monday, January 1, 2018 | 29514000 | 22540000000 |
| Tuesday, January 1, 2019 | 37121000 | 22178000000 |
| Wednesday, January 1, 2020 | 67929000 | 22084000000 |
| Friday, January 1, 2021 | 118818000 | 20118000000 |
| Saturday, January 1, 2022 | 159371000 | 19046000000 |
| Sunday, January 1, 2023 | 213894000 | 20112000000 |
| Monday, January 1, 2024 | 21969000000 |
Data in motion
In the world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Johnson & Johnson and BioCryst Pharmaceuticals, Inc. have shown contrasting trends in their SG&A costs. From 2014 to 2023, Johnson & Johnson's SG&A expenses have remained relatively stable, fluctuating around $20 billion annually. In contrast, BioCryst Pharmaceuticals has seen a dramatic increase, with expenses rising from approximately $7 million in 2014 to over $213 million in 2023, marking a staggering 2,765% increase.
This divergence highlights the different scales and strategies of these companies. While Johnson & Johnson maintains a steady course, BioCryst's growth in SG&A expenses reflects its aggressive expansion and investment in new markets. Understanding these trends provides valuable insights into the operational strategies of these pharmaceutical giants.
Who Optimizes SG&A Costs Better? Johnson & Johnson or Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: Johnson & Johnson vs Biogen Inc.
Breaking Down SG&A Expenses: Johnson & Johnson vs Insmed Incorporated
Comparing SG&A Expenses: Johnson & Johnson vs Apellis Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Johnson & Johnson vs Soleno Therapeutics, Inc.
Revenue Insights: Johnson & Johnson and BioCryst Pharmaceuticals, Inc. Performance Compared
Cost Management Insights: SG&A Expenses for Johnson & Johnson and Wave Life Sciences Ltd.
Johnson & Johnson or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: United Therapeutics Corporation vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Breaking Down SG&A Expenses: Incyte Corporation vs BioCryst Pharmaceuticals, Inc.
Ligand Pharmaceuticals Incorporated or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Amphastar Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.